BusinessVaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)By Nasdaq OMXOct 26, 2017, 2:23 PM UTC
BusinessBluePrint Phase 2 Demonstrates Digital Pathology Review Equivalent to Glass SlidesBy Nasdaq OMXOct 18, 2017, 1:45 AM UTC
BusinessWorld Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer InterventionsBy Nasdaq OMXOct 17, 2017, 6:08 AM UTC
BusinessWorld Conference on Lung Cancer Monday Press Conference: Dangers of Smoking and Lung Cancer Intervention ResearchBy Nasdaq OMXOct 16, 2017, 6:40 AM UTC
BusinessWorld Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global GuidelinesBy Nasdaq OMXOct 15, 2017, 7:26 AM UTC
BusinessThe International Association for the Study of Lung Cancer Announces Abstract Selections for the 18th World Conference on Lung CancerBy Nasdaq OMXSep 7, 2017, 6:00 PM UTC
BusinessThe International Association for the Study of Lung Cancer Announces the IASLC 18th World Conference on Lung CancerBy Nasdaq OMXJul 13, 2017, 4:02 PM UTC
BusinessLung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib TherapyBy Nasdaq OMXJul 10, 2017, 5:09 PM UTC
